DelveInsight's Short-Acting Insulin Market Insights report provides the current and forecast market analysis, individual ...

The short-acting insulin market is set for substantial growth, driven by rising diabetes prevalence, technological ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

Clinical trials of a new, once-a-week insulin have shown that it controls blood sugar as well as daily injections of an ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Everyone with type 1 diabetes in the trial also used a short-acting insulin at mealtimes. In July, Lilly rival Novo Nordisk (NOVOb.CO), opens new tab failed to secure U.S. approval for its own ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Type 2 diabetes is characterized by the body's inability to use insulin effectively. Insulin is a hormone that helps regulate metabolism properly. The condition is the most common type of ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

LAS VEGAS, Sept. 5, 2024 /PRNewswire/ -- DelveInsight's Short-Acting Insulin Market Insights report provides the current and forecast market analysis, individual leading short-acting insulin ...